灵康药业
(603669)
| 流通市值：42.63亿 | | | 总市值：42.63亿 |
| 流通股本：7.21亿 | | | 总股本：7.21亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 231,030,545.43 | 141,477,918.59 | 76,861,627.55 | 196,831,359.94 |
| 营业收入 | 231,030,545.43 | 141,477,918.59 | 76,861,627.55 | 196,831,359.94 |
| 二、营业总成本 | 269,783,181.71 | 173,780,539.6 | 94,759,740.05 | 353,767,840.88 |
| 营业成本 | 131,550,413.16 | 77,719,392.58 | 33,008,973.81 | 104,966,744.13 |
| 税金及附加 | 2,204,406.23 | 1,435,160.22 | 660,144.31 | 5,074,830.75 |
| 销售费用 | 75,164,260.53 | 44,248,597.92 | 38,117,162.41 | 120,336,536.58 |
| 管理费用 | 64,913,652.88 | 38,899,006.75 | 18,533,544.17 | 93,780,990.66 |
| 研发费用 | 14,987,666.9 | 10,639,383.76 | 4,772,080.07 | 29,124,769.54 |
| 财务费用 | -19,037,217.99 | 838,998.37 | -332,164.72 | 483,969.22 |
| 其中:利息费用 | 6,504,446.24 | 1,537,387.99 | 162,796.89 | 3,709,839.82 |
| 其中:利息收入 | 1,040,655.66 | 722,449.05 | 510,053.48 | 3,308,542.32 |
| 加:公允价值变动收益 | 1,745,296.94 | -3,180,737.13 | -2,838,771.23 | -10,717,857.79 |
| 加:投资收益 | -11,987,579.54 | -7,961,037.02 | -3,417,704.43 | -3,816,654.81 |
| 资产处置收益 | -2,250,203.86 | -2,251,564.26 | - | 83,625.67 |
| 资产减值损失(新) | -46,298.03 | -43,094.1 | -24,702.83 | -7,687,473.26 |
| 信用减值损失(新) | -16,226,317.27 | -14,873,835.03 | 805,413.53 | -10,053,229.8 |
| 其他收益 | 14,520,400.49 | 13,992,693.94 | 6,165,670.4 | 40,147,358.75 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -52,997,337.55 | -46,620,194.61 | -17,208,207.06 | -148,980,712.18 |
| 加:营业外收入 | 5,573,437.97 | 5,573,369.49 | 1,098,166.75 | 214,809.05 |
| 减:营业外支出 | 278,905.33 | 143,622.2 | 75,230.79 | 2,188,793.88 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -47,702,804.91 | -41,190,447.32 | -16,185,271.1 | -150,954,697.01 |
| 减:所得税费用 | -812,916.68 | -790,258.41 | -143,764.96 | 540,838.42 |
| 六、净利润 | -46,889,888.23 | -40,400,188.91 | -16,041,506.14 | -151,495,535.43 |
| 持续经营净利润 | -46,889,888.23 | -40,400,188.91 | -16,041,506.14 | -151,495,535.43 |
| 归属于母公司股东的净利润 | -46,889,888.23 | -40,400,188.91 | -16,041,506.14 | -151,495,535.43 |
| (一)基本每股收益 | -0.07 | -0.06 | -0.02 | -0.21 |
| (二)稀释每股收益 | -0.07 | -0.06 | -0.02 | -0.21 |
| 九、综合收益总额 | -46,889,888.23 | -40,400,188.91 | -16,041,506.14 | -151,495,535.43 |
| 归属于母公司股东的综合收益总额 | -46,889,888.23 | -40,400,188.91 | -16,041,506.14 | -151,495,535.43 |
| 公告日期 | 2024-10-31 | 2024-08-24 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |